Clinical trials: Fibroblast Growth Factor Receptor
Cancer
Roll-over Study to Continue Treatment With the Investigational Drug Rogaratinib and to Further Test Its Safety
The purpose of this study is to enable patients, who are currently receiving rogaratinib in a Bayer-sponsored clinical trial (incl. NCT01976741), to continue treatment after their respective study has been closed.
- Trial name
- NCT04125693
- Testing
- Rogaratinib (BAY1163877), Combination drug
- Where
- Switzerland
- Volunteers
- 1 people
- Sponsor
- Bayer
Urinary Bladder Neoplasms, Urologic Neoplasms
A Study of Vepugratinib (LY3866288) in Adults With Non-Muscle Invasive Bladder Cancer and Upper Tract Urothelial Cancer
The main purpose of this study is to see how well vepugratinib works in adults with low grade, intermediate risk, non-muscle invasive bladder cancer (LG IR NMIBC) or low-grade upper tract urothelial carcinoma (LG UTUC).
- Conditions
- Urinary Bladder Neoplasms, Urologic Neoplasms, Receptor, Fibroblast Growth Factor, Type 3
- Trial name
- FORAY (NCT07827612)
- Testing
- Vepugratinib
- Where
- United States
- Volunteers
- 161 people
- Sponsor
- Eli Lilly and Company
Advanced Solid Tumor
A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-C137 alone and in combination with anticancer agents in participants with…
- Trial name
- NCT06625593
- Testing
- BG-C137, Anticancer Agents
- Where
- 52 sites in United States, Australia and 2 more
- Volunteers
- 168 people
- Sponsor
- BeOne Medicines
Medical Oncology
Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)
To evaluate the safety, tolerability, maximum tolerated dose, pharmacokinetics, and pharmacodynamics of the anti-FGFR2 antibody drug conjugate BAY1187982 in subjects with advanced solid tumors known to express fibroblast growth…
- Trial name
- NCT02368951
- Testing
- BAY1187982
- Where
- 13 sites in United States, Singapore and 1 more
- Volunteers
- 20 people
- Sponsor
- Bayer
Carcinoma, Hepatocellular
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 (Erdafitinib) in Participants With Advanced Hepatocellular Carcinoma
The purpose of this study is to determine recommended Phase 2 dose [RP2D]) and the objective response rate of JNJ-42756493 (erdafitinib) in advanced hepatocellular carcinoma (HCC) participants with fibroblast growth factor (FGF)…
- Trial name
- NCT02421185
- Testing
- JNJ-42756493 (erdafitinib)
- Where
- 10 sites in China, South Korea and 1 more
- Volunteers
- 53 people
- Sponsor
- Janssen Research & Development, LLC
Urinary Bladder Neoplasms, Receptors, Fibroblast Growth Factor
A Study of Erdafitinib Intravesical Delivery System in Japanese Participants With Bladder Cancer
The purpose of the study is to determine the tolerability of erdafitinib intravesical delivery system (TAR-210) in Japanese participants.
- Trial name
- TAR-210 (NCT05567185)
- Testing
- Erdafitinib Intravesical Delivery System
- Where
- 4 sites in Japan
- Volunteers
- 5 people
- Sponsor
- Janssen Pharmaceutical K.K.
Biliary Tract Cancer
A Post-marketing Observational Study of Tasfygo in Participants With Unresectable Biliary Tract Cancer With Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene Positivity Who Progressed After Chemotherapy
The primary purpose of this study is to investigate the safety of Tasfygo.
- Trial name
- NCT06793709
- Testing
- No Intervention
- Where
- Japan
- Volunteers
- 60 people
- Sponsor
- Eisai Co., Ltd.
Advanced or Metastatic Solid Tumor
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
The primary objective of this study is to determine the safety, tolerability, maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) and efficacy of rogaratinib in combination with copanlisib in patients with locally…
- Trial name
- ROCOCO (NCT03517956)
- Testing
- Rogaratinib (BAY1163877), Copanlisib (BAY80-6946)
- Where
- 20 sites in United States, Belgium and 4 more
- Volunteers
- 16 people
- Sponsor
- Bayer
Urothelial Carcinoma
Derazantinib and Atezolizumab in Patients With Urothelial Cancer
The purpose of this study was to evaluate efficacy of derazantinib monotherapy or derazantinib-atezolizumab in combination in patients with advanced urothelial cancer harboring fibroblast growth factor receptor (FGFR) genetic…
- Trial name
- FIDES-02 (NCT04045613)
- Testing
- Derazantinib 300 mg once daily monotherapy, Derazantinib 200 mg once daily + atezolizumab 1200 mg, Derazantinib 300 mg once daily+ atezolizumab 1200 mg
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 95 people
- Sponsor
- Basilea Pharmaceutica
Neoplasms, Lymphoma
A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma
The purpose of this study is to determine a dose for future development and to evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy profiles of JNJ-42756493 in Japanese and other Asian patients with advanced or…
- Conditions
- Neoplasms, Lymphoma, Adenocarcinoma, Esophagogastric Junction
- Trial name
- NCT01962532
- Testing
- Part 1: JNJ-42756493, Part 2: JNJ-42756493
- Where
- 3 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Research & Development, LLC
Hypochondroplasia
An Interventional Study of Infigratinib in Children With Hypochondroplasia
ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children with hypochondroplasia (HCH) receiving infigratinib at one of two doses…
- Trial name
- HCH (NCT06873035)
- Testing
- infigratinib 0.128 mg/kg/day, infigratinib 0.25 mg/kg/day
- Where
- 24 sites in United States, Australia and 8 more
- Volunteers
- 24 people
- Sponsor
- QED Therapeutics, a BridgeBio company
Cholangiocarcinoma
Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
- Trial name
- NCT02924376
- Testing
- Pemigatinib
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 147 people
- Sponsor
- Incyte Corporation
Solid Tumors
A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)
The purpose of this study is to evaluate the safety and tolerability of pemigatinib in Japanese subjects with advanced malignancies.
- Trial name
- NCT03235570
- Testing
- Pemigatinib
- Where
- 12 sites in Japan
- Volunteers
- 44 people
- Sponsor
- Incyte Corporation
Solid Tumours
Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
This study is primarily designed to assess the safety and the tolerability of Debio1347 (CH5183284) in patients with advanced solid malignancies, whose tumours have an alteration of the Fibroblast Growth Factor Receptor (FGFR) 1…
- Trial name
- NCT01948297
- Testing
- Debio1347 (CH5183284)
- Where
- 8 sites in United States, Singapore and 3 more
- Volunteers
- 77 people
- Sponsor
- Debiopharm International SA
Urothelial Carcinoma
A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC
This trial is an open, phase II clinical study. The study is divided into two parts: A and B, and the part A evaluate the safety and tolerability of AZD4547 combined with Tislelizumab in patients with locally advanced or…
- Trial name
- NCT05775874
- Testing
- AZD4547, Tislelizumab
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Abbisko Therapeutics Co, Ltd
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants…
- Trial name
- FORTITUDE-101 (NCT05052801)
- Testing
- Bemarituzumab, mFOLFOX6
- Where
- 300 sites in United States, Argentina and 35 more
- Volunteers
- 547 people
- Sponsor
- Amgen
MPN (Myeloproliferative Neoplasms)
A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib (INCB054828) in subjects with myeloid/lymphoid neoplasms with fibroblast growth factor receptor (FGFR) 1 rearrangement.
- Trial name
- NCT03011372
- Testing
- Pemigatinib
- Where
- 33 sites in United States, Austria and 9 more
- Volunteers
- 47 people
- Sponsor
- Incyte Corporation